Spruce Biosciences (SPRB) announced that the FDA has granted breakthrough therapy designation to tralesinidase alfa enzyme replacement therapy for the treatment of Sanfilippo Syndrome Type B.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SPRB: